US Broker Ratings

Novartis AG (NVS) Stock Analysis: A Look into the Healthcare Giant’s Growth Potential

Novartis AG, a titan in the healthcare sector, stands as a formidable player in the pharmaceuticals industry, with a robust market capitalization of $296.61 billion. With its headquarters nestled in..

Eli Lilly and Company (LLY): Analyst Consensus Highlights 23.54% Potential Upside

Eli Lilly and Company (NYSE: LLY), a stalwart in the healthcare sector, has been attracting significant attention from investors, thanks to its robust market presence and impressive growth metrics. With..

Emergent BioSolutions Inc. (EBS) Investor Outlook: Analyzing a 47.6% Potential Upside

Emergent BioSolutions Inc. (NYSE: EBS), a key player in the healthcare sector, specializes in providing preparedness and response solutions for public health threats. With a market capitalization of $426.99 million,..

Maze Therapeutics, Inc. (MAZE): Investor Outlook and Analyst Ratings Point to Strong Growth Potential

Maze Therapeutics, Inc. (NASDAQ: MAZE) is capturing the attention of investors with a compelling blend of innovation in the biotechnology sector and promising analyst ratings. Headquartered in South San Francisco,..

Standard BioTools Inc. (LAB) Stock Analysis: Exploring a 66.58% Potential Upside in the Medical Devices Sector

Standard BioTools Inc. (NASDAQ: LAB), a noteworthy player in the healthcare sector specializing in medical devices, offers a tantalizing prospect for investors with its potential upside of 66.58%. With a..

Tectonic Therapeutic, Inc. (TECX): Investor Outlook on a Biotech Innovator with a 129% Upside Potential

Tectonic Therapeutic, Inc. (NASDAQ: TECX) is capturing the attention of investors with its innovative approach in the biotechnology sector, particularly focusing on the modulation of G protein coupled receptors (GPCRs)..

Humacyte, Inc. (HUMA) Stock Analysis: Unveiling a Potential 576% Upside in Biotech

Humacyte, Inc. (NASDAQ: HUMA), a pioneering biotechnology company in the healthcare sector, is capturing investor attention with its ambitious focus on bioengineered human tissues. Based in Durham, North Carolina, Humacyte..

Abivax SA (ABVX): Investor Outlook with a 32.67% Potential Upside and Strong Analyst Support

Abivax SA (ABVX), a France-based biotechnology firm, is currently capturing the attention of investors with its promising potential upside of 32.67%. This clinical-stage company is renowned for its focus on..

Oruka Therapeutics, Inc. (ORKA) Stock Analysis: 81% Potential Upside Sparks Investor Interest

In the dynamic world of biotechnology, Oruka Therapeutics, Inc. (NASDAQ: ORKA) is rapidly gaining attention. With its focus on developing cutting-edge monoclonal antibody therapeutics for psoriasis and other inflammatory conditions,..

AngioDynamics, Inc. (ANGO) Investor Outlook: An 80% Upside Potential Amid Strategic Healthcare Innovations

AngioDynamics, Inc. (NASDAQ: ANGO), a key player in the healthcare sector, is making waves with its innovative medical technologies. With a market capitalization of $441.44 million, this Latham, New York-based..

Kamada Ltd. (KMDA) Stock Analysis: Analyst Ratings Project a Promising 49.6% Upside

Kamada Ltd. (NASDAQ: KMDA), a key player in the healthcare sector focusing on plasma-derived protein therapeutics, is drawing investor attention with its promising growth trajectory. Headquartered in Rehovot, Israel, Kamada..

Altimmune, Inc. (ALT) Stock Analysis: Exploring a 378% Potential Upside Amidst Biopharmaceutical Innovation

Altimmune, Inc. (NASDAQ: ALT), a clinical-stage biopharmaceutical company, has been drawing significant attention in the biotechnology sector with its ambitious focus on tackling obesity, metabolic, and liver diseases. Headquartered in..

Bioventus Inc. (BVS) Stock Analysis: Exploring a 74% Potential Upside in the Medical Device Sector

Bioventus Inc. (NASDAQ: BVS), a prominent player in the healthcare sector, is capturing the attention of investors with a notable 74.42% potential upside, according to recent analyst ratings. Headquartered in..

MeiraGTx Holdings plc (MGTX) Investor Outlook: Exploring a 250% Upside Potential in the Biotechnology Sector

In the dynamic world of biotechnology, few companies offer the tantalizing upside potential that MeiraGTx Holdings plc (NASDAQ: MGTX) does. With a potential upside of 250.13%, this clinical-stage genetics medicines..

Oric Pharmaceuticals, Inc. (ORIC) Stock Analysis: Unveiling an 80.53% Potential Upside for Investors

Oric Pharmaceuticals, Inc. (NASDAQ: ORIC) has been capturing the attention of investors with its promising pipeline and strategic partnerships in the biotechnology sector. As a clinical-stage biopharmaceutical company, Oric Pharmaceuticals..

Septerna, Inc. (SEPN) Stock Analysis: Unveiling a Biotech Gem with 65.84% Upside Potential

Septerna, Inc. (NASDAQ: SEPN) stands as a dynamic player in the biotechnology sector, capturing investor attention with a staggering potential upside of 65.84%. As a clinical-stage company, Septerna is deeply..

Rapport Therapeutics, Inc. (RAPP) Stock Analysis: 82% Upside Potential Sparks Interest in Biotech Innovator

Investors focusing on the biotechnology sector might want to take a closer look at Rapport Therapeutics, Inc. (NASDAQ: RAPP), a clinical-stage biopharmaceutical company that has been making waves with its..

SIGA Technologies Inc. (SIGA) Stock Analysis: Navigating the Health Security Market Amid Revenue Challenges

Investors eyeing SIGA Technologies Inc. (NASDAQ: SIGA) should consider both its potential and challenges within the healthcare sector. As a commercial-stage pharmaceutical company specializing in health security, SIGA’s flagship product,..

Talkspace, Inc. (TALK) Stock Analysis: Navigating a 19.42% Potential Upside in the Digital Health Arena

Talkspace, Inc. (NASDAQ: TALK) is making waves in the digital healthcare sector, offering a unique investment opportunity as it continues to expand its footprint in the virtual behavioral health market...

Amylyx Pharmaceuticals (AMLX) Stock Analysis: Investors Eye a Promising 55% Upside Potential

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX), a clinical-stage pharmaceutical company based in Cambridge, Massachusetts, is capturing the attention of investors with its forward-looking pipeline in the healthcare sector. Specializing in the..

Search

Funds

US Broker Ratings

Search

Funds

US Broker Ratings

FTSE 100

Funds